Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced the launch of the Viz Pulmonary™ Suite, an integrated AI-powered solution in the Viz.ai enterprise platform, designed to help health systems streamline care delivery for pulmonary conditions. The suite brings acute and chronic pulmonary workflows together in a single solution, giving clinicians a more streamlined way to manage patients to help get them on guideline-directed care.

With 55%-65% of potential in-network referrals lost due to health system leakage,¹ improving continuity across the patient journey becomes a critical challenge. The Viz Pulmonary Suite, which integrates seamlessly with EHR systems, is designed to help pulmonary teams improve retention and outcomes by combining context-aware patient summaries and guideline surfacing with specialized tools for major pulmonary conditions, including chronic obstructive pulmonary disease (COPD), lung nodules, and pulmonary embolism—with the goal of preventing missed diagnoses and treatment delays. Early findings are showing promising results for Viz.ai’s network of healthcare partners. The Viz Pulmonary Suite includes Viz PE, which was shown to reduce time to treatment from 1.75 days to 0.56 days and lowered in-hospital mortality among high-risk PE patients in a single-center study.²

“Pulmonary care breaks down not because we lack treatments, but because patients may be lost between moments of care,” said Tim Showalter, MD, Chief Medical Officer of Viz.ai. “Across COPD, pulmonary embolism, and lung nodules, critical findings are often identified but not acted on in time due to fragmented workflows. The Viz Pulmonary Suite brings identification, coordination, and follow-through into a single solution that is fully integrated with the EHR, helping clinicians intervene earlier and manage these patients with greater consistency.”

Breakdowns in identification and follow-up are common for the more than 34 million adults living with some form of chronic lung disease. Nearly half of COPD patients hospitalized for acute exacerbations are readmitted within 30 days.³ Up to 71% of clinically significant lung nodules go without appropriate follow-up.⁴ And in pulmonary embolism, up to 79% of incidental cases are missed on initial imaging,⁵ even though 67% of those missed emboli are clinically significant.⁶

"As patients move through imaging, the ER, and acute care visits, their journey often becomes fragmented. Consistent coordination can be challenging, especially for conditions like chronic obstructive pulmonary disease, pulmonary embolism, and lung nodules that depend on well-managed care pathways," said Lakshman Swamy, MD, MBA, FCCP, Chief Pulmonologist at Monogram Health. "Solutions like the Viz Pulmonary Suite provide clinical teams with connected AI-enabled workflows to help identify potential patients earlier, act more efficiently, and support more consistent follow-up across the care continuum.”